Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sosei Heptares Eyes $3bn Sales From IBD Drug Returned By GSK

Executive Summary

The first-in-class, oral GPR35 agonist has shown preclinical promise as a potential treatment for gastrointestinal indications such as ulcerative colitis.

You may also be interested in...



Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug

Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.

GSK Reorganizes Around Key R&D Areas As Lepore Exits

The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.

Sosei Builds APAC Independence Through Idorsia Deal

Sosei Heptares' acquisition of Idorsia's ex-China APAC operations will give the Japan-UK group ready-made independent development and commercialization capabilities in Japan, accelerating by "five to 10 years" its goals in its home market, its CEO tells Scrip. The deal also brings a marketed drug and options to selected Idorsia pipeline assets. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel